Cartilage boundary lubrication synergism is mediated by hyaluronan concentration and PRG4 concentration and structure by unknown
RESEARCH ARTICLE Open Access
Cartilage boundary lubrication synergism is
mediated by hyaluronan concentration and
PRG4 concentration and structure
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Abstract
Background: Proteoglycan 4 (PRG4) and hyaluronan (HA) are key synovial fluid constituents that contribute
synergistically to cartilage boundary lubrication; however, the effects of their concentrations as well as their
structure, both of which can be altered in osteoarthritis, on this functional synergism are unknown. The objectives
of this study were to evaluate cartilage boundary lubricating ability of 1) PRG4 + HA in solution at constant HA
concentration in a range of PRG4 concentrations, 2) constant PRG4 concentration in a range of HA concentrations,
3) HA + reduced/alkylated (R/A) PRG4, and 4) hylan G-F 20 + PRG4.
Methods: Static and kinetic friction coefficients (μstatic,Neq, <μkinetic,Neq>) were measured using a previously
characterized cartilage-cartilage boundary mode friction test for the following concentrations of purified PRG4
and HA: Test 1: HA (1.5 MDa, 3.3 mg/mL) + PRG4 from 4.5 – 1500 μg/mL; Test 2: PRG4 (450, 150, 45 μg/mL)
+ HA (1.5 MDa) from 0.3 – 3.3 mg/mL. Test 3: hylan G-F 20 (3. 3 mg/mL) + PRG4 (450 μg/mL). Test 4: HA
(3.3 mg/mL) + R/A PRG4 (450 μg/mL). ANOVA was used to compare lubricants within (comparing 6 lubricants
of interest) and between (comparing 3 lubricants of interest) test sequences, with Tukey and Fishers post-hoc
testing respectively.
Results: This study demonstrates that both PRG4 and HA concentration, as well as PRG4 disulfide-bonded
structure, can alter the cartilage boundary lubricating ability of PRG4 + HA solutions. The boundary lubricating
ability of high MW HA + PRG4 solutions was limited by very low concentrations of PRG4. Decreased
concentrations of high MW HA also limited the cartilage boundary lubricating ability of HA + PRG4 solutions,
with the effect exacerbated by low PRG4 concentrations. The reduction of friction by addition of PRG4 to a
cross-linked HA viscosupplement product, but not with addition of R/A PRG4 to HA, is consistent with a non-covalent
mechanism of interaction where tertiary and quaternary PRG4 structure are important.
Conclusions: Collectively, these results demonstrate that deficiency of either or both PRG4 and HA, or alterations
in PRG4 structure, may be detrimental to SF cartilage boundary lubricating function. This study provides further
insight into the nature of cartilage boundary lubrication and advancement towards potential formulation of new
intra-articular biotherapeutic treatments for osteoarthritis using PRG4 ± HA.
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Background
Friction between articular cartilage surfaces in motion is
mediated through a combination of lubrication mecha-
nisms. During fluid film lubrication, cartilage surfaces
are separated by a fluid layer, while during boundary
lubrication friction is mediated by interactions between
lubricant molecules adsorbed to the surface [1]. The
boundary lubrication mode becomes increasingly dom-
inant as loading time is increased and interstitial fluid is
depressurized [2, 3]. Furthermore, opposing cartilage
surfaces make contact over only approximately 10 % of
the total area, making these areas of contact vulnerable
to high friction [4]. Synovial fluid (SF) constituents pro-
teoglycan 4 (PRG4) and hyaluronan (HA) are the primary
contributors to its cartilage boundary lubricating ability
[5]. PRG4 [6] is a mucin-like O-linked glycosylated protein
present in SF [7] and at the articular cartilage surface [8].
HA, a linear polymer of D-glucuronic acid and D-N-
acetylglucosamine [9], is also present in SF. Alone, solu-
tions of PRG4 or HA reduce friction in a dose-dependent
manner at a cartilage-cartilage biointerface in a boundary
mode of lubrication compared to phosphate buffered
saline (PBS). When combined at physiological concentra-
tions, PRG4 +HA further reduce friction synergistically
towards that of whole SF. [5] Both PRG4 and HA are crit-
ical to the cartilage boundary lubricating function of SF,
and decreased boundary lubricating ability of SF has been
linked with increased wear at the articular surface [10].
While the molecular mechanism of the PRG4 +HA syn-
ergism at a cartilage-cartilage biointerface in a boundary
mode of lubrication remains to be fully understood, some
characterization of potential factors affecting the syner-
gism in vitro has previously been performed. In solutions
of HA alone, friction coefficients decrease with increasing
HA concentration [5, 11], and slightly with increasing
molecular weight (MW, from 20 kDa to 5 MDa, at a
concentration of 3.3 mg/ml) [11, 12]. However, upon
addition of PRG4 at 450 μg/mL the dependence of friction
coefficient on HA MW is no longer observed [12] and
friction is reduced to a similar value by addition of PRG4
over the range of MW of the 3.3 mg/ml HA solutions.
Some SF from patients with osteoarthritis (OA) is defi-
cient in PRG4, has normal HA concentration, an HA
MW distribution shifted towards the lower range over all
sizes from 6 MDa to 0.5 MDa, and fails to lubricate as well
as normal SF. Normal cartilage boundary lubricating abil-
ity could be restored with addition of PRG4 to the SF [13],
as evidenced by a measured reduction in friction. A simi-
lar decrease in SF HA concentration and HA MW,
although with an increase in PRG4 concentration, has
been observed in an equine acute injury model; this SF
also fails to lubricate, though cartilage boundary lubricat-
ing ability could be restored by supplementation with high
MW HA (4 MDa), but not low MW HA (800 kDa) [11].
These studies collectively demonstrate that both PRG4
and HA, particularly high MW HA, are necessary contrib-
utors to the cartilage boundary lubricating function of SF.
However, the potential concentration dependence of
PRG4 and/or high MW HA, both of which can be dimin-
ished in diseased SF, of the functional friction-reducing
PRG4 +HA synergism at a cartilage-cartilage biointerface
remains to be fully clarified.
The effects of injury and disease on PRG4 structure in
SF, including relative composition of multimers:mono-
mers and fragments of PRG4 [14], remain to be fully eluci-
dated. As PRG4 is known to be degraded by enzymes
such as neutrophil elastase, which can be up-regulated in
inflammatory conditions such as post-anterior cruciate
ligament tear [15], the ability of its fragments to maintain
their ability to interact with HA may be of functional sig-
nificance. The lubricating ability of PRG4 is decreased
after it is reduced and alkylated (R/A) to break both inter-
and intra-molecular disulfide bonds [16], and preparations
of PRG4 enriched in disulfide-bonded multimeric species
provide enhanced lubricating ability compared to prepara-
tions enriched in monomeric PRG4 [17]; this demon-
strates the functional importance of inter-molecular
disulfide bonds specifically, as reduced preparations of
monomers appear to lubricate as well as non-reduced
monomers [18]. Furthermore, R/A decreases the ability of
PRG4 to adsorb to cartilage surfaces [19]. However, the
effect of loss of disulfide-bonded structure, which may
occur in diseased SF, by R/A on PRG4’s ability to interact
with HA and synergistically reduce friction in a boundary
mode at a cartilage-cartilage biointerface is also unknown.
Lastly, the MW of HA has also been linked to its
efficacy as an intra-articular viscosupplement. Intra-
articular HA injections are currently used to treat pain in
OA patients, and it is thought that increasing the MW of
HA by cross-linking increases joint residence time [20].
Increased MW may also contribute to pain relief by in-
creased protection of nerve endings via increased viscosity
[21]. Hylan G-F 20 (“Synvisc”, Genzyme) is one such
example of a cross-linked HA preparation currently avail-
able and used clinically for intra-articular injections [22].
Given the clinical utility of cross-linked HA preparations,
and evidence for intra-articular administration of PRG4’s
potential efficacy in preventing joint degradation in animal
models of OA [23–26], the ability of cross-linked HA to
functionally interact with PRG4 synergistically to reduce
friction in a boundary mode at a cartilage biointerface,
towards that of whole SF, is of significant interest and
currently unknown.
Given the limited level of understanding pertaining to
the concentration and structural dependency of PRG4 +
HA synergistic cartilage boundary lubrication function,
and the clinical correlations of SF cartilage boundary lu-
bricant composition and function to joint health and
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disease, the objectives of this study were as follows: to
evaluate cartilage boundary lubricating ability of 1)
PRG4 +HA in solution at constant HA concentration in
a range of PRG4 concentrations, 2) constant PRG4
concentration in a range of HA concentrations, 3) HA +
R/A PRG4, and 4) hylan G-F 20 + PRG4.
Methods
Materials
Materials for lubrication testing were obtained as de-
scribed previously [12]. HA of 1.5 MDa MW was obtained
from Lifecore Biomedical LLC (Chaska, MN, USA), and
bovine SF was obtained from Animal Technologies (Tyler,
TX, USA). Skeletally mature bovine stifle joints (equiva-
lent to a human knee joint) were obtained from a local
slaughterhouse (Calgary, AB, Canada) under approval by
the Animal Care Committee at the University of Calgary.
Hylan G-F 20 was from Sanofi Canada (Laval, QC,
Canada). PRG4 was purified from culture media condi-
tioned by mature bovine cartilage explants, as described
previously [5]. Purity of the PRG4 preparation was con-
firmed by 3–8 % Tris-Acetate SDS-PAGE followed by pro-
tein stain and Western blotting with anti-PRG4 antibody
5C11 (obtained from Millipore, Etobicoke, ON, Canada)
[27] with Invitrogen’s NuPAGE system. Concentration of
the purified PRG4 was determined by bicinchoninic acid
assay.
Lubricants were prepared by combining the required
volumes of PRG4 (prepared in PBS) and HA (prepared
in PBS) at the appropriate concentrations. Hylan G-F 20
(initially 8.0 mg/mL) was diluted to 3.3 mg/mL in PBS.
R/A PRG4 was prepared in PBS by incubation with
10 mM dithiothreitol for 2 h at 60 °C and then 40 mM
sodium iodoacetate for 2 h at room temperature in the
dark [27], followed by dialysis against PBS overnight at
37 °C. R/A was confirmed by SDS-PAGE followed by
protein staining [28]. Figure 1 demonstrates the purity
of the PRG4 preparation as well as confirmation of R/A
of PRG4.
Sample preparation
Annulus and core shaped osteochondral samples (N = 42
pairs) were harvested from the patellofemoral groove of
11 skeletally mature bovine stifle joints as described pre-
viously [29]. An annular contact area was used to reduce
variations in speed across the cartilage surfaces. Samples
were rinsed vigorously overnight in ~40 mL of PBS at
4 °C to remove residual SF from the cartilage surface.
Samples were then stored at −80 °C in PBS with prote-
ase inhibitors until the day prior to testing, at which
time they were thawed and again rinsed vigorously over-
night in PBS. Samples were then bathed in the next day’s
test lubricant (0.2 mL for core, 0.1 mL for annulus), such
that the cartilage surface was completely immersed, at
4 °C overnight prior to lubrication testing.
Lubrication testing
Lubrication tests were performed on a Bose ELF 3200
using a previously characterized in vitro cartilage-on-
cartilage boundary mode lubrication test. [29] Briefly,
annulus and core shaped osteochondral samples were
opposed against each other, resulting in a stationary
contact area, compressed to 18 % of the total cartilage
thickness at 0.002 mm/s, and an interstitial fluid
depressurization period of 40 minutes was allowed result-
ing in ~0.09 MPa compressive stress. Without removal of
this equilibrium load (Neq) samples were then left opposed
under Neq for pre-sliding durations (Tps) of 1200, 120, 12,
and 1.2 s, and rotated +2 revolutions and −2 revolutions
at 0.3 mm/s after each Tps. This test sequence was then
repeated in the opposite direction of rotation. Using the
Neq, static (μstatic,Neq), and kinetic (<μkinetic,Neq>) coeffi-
cients of friction were calculated [29], representing the
resistance to the onset of motion and steady motion,
respectively. Because < μkinetic,Neq > increased only slightly
with Tps, with values at Tps = 1.2 s being on average
within ~18 % of those at Tps = 1200 s, for brevity and
clarity, and as done previously [5], only < μkinetic,Neq > at
Tps = 1.2 s will be presented.
In all experiments, each osteochondral pair was tested
sequentially over 4–5 days in each of the 4–5 test
Fig. 1 Characterization of PRG4 and reduced and alkylated (R/A)
PRG4. Protein stain on 3-8 % Tris-Acetate SDS-PAGE stained with
SimplyBlue SafeStain (a) and immunoreactivity with anti-PRG4 antibody
5C11 (b). ** and * indicate high MW multimeric species and
monomeric PRG4 species, respectively, with the former being
present in the non-reduced samples and absent from the
R/A PRG4
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lubricants. Lubricants were selected in order of pre-
dicted increasing lubricating ability to minimize carry-
over effects. In all tests, PBS served as the negative
control lubricant and bovine SF served as the positive
control lubricant. PRG4 and HA concentrations were
selected to represent values lower, similar, and higher, to
those observed in normal human SF [13].
Lubricant sequences
Four sets of tests were performed to evaluate cartilage
boundary lubricating ability of varying concentrations of
PRG4 and HA, as well that of hylan G-F 20 ± PRG4 and
HA+ R/A PRG4. Lubricant sequences for each test are
shown in Table 1. To determine the effect of PRG4 con-
centration on PRG4 +HA cartilage boundary lubricating
ability in a constant [HA] = 3.3 mg/mL, a high dose of
PRG4 (Test 1A , 150 – 1500 μg/mL, N = 6) and a low dose
of PRG4 (Test 1B, 4.5 – 150 μg/mL, N = 4) were per-
formed. Test sequences 1A and 1B were pooled for ana-
lysis. To determine the effect of HA concentration on
PRG4 +HA cartilage boundary lubricating ability in con-
stant [PRG4] three test sequences using HA concentra-
tions ranging from 0.3 – 3.3 mg/mL were performed in
PRG4 concentrations of 450 (Test 2A, N = 8), 150 (Test
2B, N = 4) and 45 μg/mL (Test 2C, N = 4). Results were
compared between the 3 test sequences at each HA con-
centration. The cartilage boundary lubricating ability of
HA combined with R/A PRG4 (disruption of tertiary and
quaternary structure, inter- and intra-molecular disulfide
bonds are broken), was evaluated compared to the lubri-
cating ability of HA alone and HA with non-reduced
PRG4 (Test 3, N = 8). To determine the cartilage bound-
ary lubricating ability of PRG4 combined with cross-
linked HA, hylan G-F 20 was tested alone and then in
combination with PRG4 at 450 μg/mL (Test 4, N = 8).
Statistical analysis
Unless otherwise indicated, data are presented as mean
± 95 % confidence interval (upper limit, lower limit).
Data was tested for normality using Shapiro-Wilks test
and log-transformed if not normal. Non-parametric
methods (Wilcoxon signed rank test) were used if data
were not normal or normalized with log-transformation.
The effects of test lubricant and Tps (as a repeated fac-
tor) on friction coefficients, μstatic,Neq and < μkinetic,Neq>,
were assessed by repeated measures analysis of variance
(ANOVA). To compare lubricants within test sequences,
the effect of test lubricant on < μkinetic,Neq > at Tps = 1.2 s
between test lubricants and SF was assessed by ANOVA,
with Tukey post-hoc testing between the 5 lubricants of
interest. To compare lubricants between test sequences
(i.e. between the HA dose responses in the three PRG4
concentration sequences), the effect of test lubricant on
< μkinetic,Neq > at Tps = 1.2 s was assessed by ANOVA
with protected Fishers post-hoc testing between the 3
lubricants of interest. Statistical analysis was performed
using SPSS 22.0 (IBM SPSS software, New York, NY).
Results
Lubrication Testing
PRG4 dose response in HA
In constant [HA] = 3.3 mg/mL, coefficients of friction
appeared to decrease towards that of SF as [PRG4]
increased, decreasing towards a plateau between 45 and
150 μg/mL. μstatic,Neq varied with test lubricant and Tps in
both the low dose sequence (p < 0.001, p < 0.05, Fig. 2a) and
Table 1 Summary of lubricant sequences used over 4 – 5 consecutive days of testing
Test Lubricant [PRG4] (μg/mL), [HA] (mg/ml)
1 2 3 4 5
1A: PRG4 low dose, HA (N = 4) PBS [PRG4] = 4.5 [PRG4] = 45 [PRG4] = 150 SF
[HA] = 3.33 [HA] = 3.33 [HA] = 3.33
1B: PRG4 high dose, HA (N = 6) PBS [PRG4] = 150 [PRG4] = 450 [PRG4] = 1500 SF
[HA] = 3.33 [HA] = 3.33 [HA] = 3.33
2A: PRG4 high, HA dose (N = 8) PBS [PRG4] = 450 [PRG4] = 450 [PRG4] = 450 SF
[HA] = 0.3 [HA] = 1.0 [HA] = 3.33
2B: PRG4 mid, HA dose (N = 4) PBS [PRG4] = 150 [PRG4] = 150 [PRG4] = 150 SF
[HA] = 0.3 [HA] = 1.0 [HA] = 3.33
2C: PRG4 low, HA dose (N = 4) PBS [PRG4] = 45 [PRG4] = 45 [PRG4] = 45 SF
[HA] = 0.3 [HA] = 1.0 [HA] = 3.33
3: R/A PRG4, HA (N = 8) PBS [PRG4] = 0 R/A [PRG4] = 450 [PRG4] = 450 SF
[HA] = 3.33 [HA] = 3.33 [HA] = 3.33
4: PRG4, cross-linked HA (N = 8) PBS [PRG4] = 0 [PRG4] = 450 SF N/A
[HYLAN G-F 20] = 3.33 [HYLAN G-F 20] = 3.33
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high dose sequence (p < 0.001, p < 0.001, with an interaction
between the effects of lubricant and Tps on μstatic,Neq (p <
0.01), Fig. 2b). <μkinetic,Neq > at Tps = 1.2 seconds also varied
with test lubricant (p = 0.02). Values of < μkinetic,Neq > in
[PRG4] = 4.5 and 45 μg/mL were significantly higher than
those in SF (p = 0.03, 0.04). <μkinetic,Neq > in [PRG4] = 150,
450, and 1500 μg/mL were similar to each other and to SF
(p = 0.14 – 1.0, Fig. 2c).
HA dose response in PRG4
In [PRG4] = 450 μg/mL, μstatic,Neq varied with test lubri-
cant and Tps (all p <0.001, Fig. 3a). In [PRG4] = 150 μg/
mL, μstatic,Neq varied with test lubricant and Tps (p =
0.005, p < 0.0001) without an interaction (p = 0.92,
Fig. 3b). In [PRG4] = 45 μg/mL, μstatic,Neq also varied
with test lubricant and Tps (p = 0.001 and p < 0.0001)
without an interaction (p = 0.37, Fig. 3c).
When compared between test sequences, values of
< μkinetic,Neq > were higher in [PRG4] = 45 μg/mL com-
pared to those in [PRG4] = 450 μg/mL at [HA] = 0.3, 1.0
, and 3.3 mg/mL (p = 0.002, 0.03, 0.03 respectively,
Fig. 3d). At [HA] = 0.3 mg/mL, [PRG4] = 45 μg/mL was
also higher than 150 μg/mL (p = 0.007). There was no
difference between < μkinetic,Neq > for [PRG4] = 150 and
450 μg/mL at [HA] = 0.3 or 1.0 mg/mL (p = 0.82, 0.91),
however the difference was appreciable (though not
significant) at [HA] = 3.3 mg/mL (p = 0.19).
R/A PRG4
Addition of R/A PRG4 at 450 μg/mL to 1.5 MDa HA at
3.3 mg/mL appeared to slightly, but not significantly,
lower friction compared to HA alone. μstatic,Neq varied
with test lubricant and Tps (all p < 0.001, Fig. 4a). <μkine-
tic,Neq > at Tps = 1.2 s also varied with test lubricant (p <
0.0001, Fig. 4b). <μkinetic,Neq > for HA alone was signifi-
cantly higher than SF (p = 0.001). Addition of R/A PRG4
to HA did not significantly reduce < μkinetic,Neq > com-
pared to HA alone (p = 0.46), however < μkinetic,Neq > for
HA + R/A PRG4 was significantly higher than SF (p =
0.04). Addition of PRG4 to HA tended to improve lubri-
cating ability compared to HA alone (p = 0.06), and there
were no significant differences between HA + PRG4 and
HA + R/A PRG4 or SF (p = 0.65, 0.33).
Partially cross-linked HA
Addition of PRG4 at 450 μg/mL to hylan G-F 20 at 3.3 mg/
mL decreased friction compared to hylan G-F 20 alone.
Fig. 2 Effect of PRG4 concentration on cartilage boundary
lubricating ability. μstatic,Neq for PRG4 low dose (Test 1A, a), and PRG4
high dose (Test 1B, b). <μkinetic,Neq > at Tps = 1.2 s (c) for PRG4 high
and low dose response + constant [HA] = 3.3 mg/mL (Tests 1A, 1B).
Average < μkinetic,Neq > in PBS and SF shown in grey for reference. * =
significantly higher than SF (p < 0.05)
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μstatic,Neq varied with test lubricant and Tps with an inter-
action (all p < 0.0001, Fig. 5a). <μkinetic,Neq > at Tps = 1.2 s
also varied with test lubricant (p = 0.02, Fig. 5b). Hylan G-F
20 alone failed to lubricate as well as SF (p = 0.001). Hylan
G-F 20 + PRG4 was significantly lower than hylan G-F 20
alone (p = 0.04), and provided boundary lubricating ability
equivalent to that of SF (p = 0.29).
Discussion
The results described here demonstrate that concen-
tration of both PRG4 and high MW HA can affect
the ability of PRG4 + HA solutions to reduce friction
in the boundary mode at a cartilage-cartilage biointer-
face. The lubricating ability provided by the PRG4 +
HA solutions tested here approached that of whole
SF except for very low PRG4 (4.5, 45 μg/mL) concen-
trations in physiologically normal HA concentrations.
This diminished cartilage boundary lubricating ability
was enhanced when low PRG4 concentrations (45,
150 μg/mL) were added to low HA concentrations
(0.3, 1.0 mg/mL); in this case physiological levels of
PRG4 reduced friction, but not to the same level as
when combined with higher HA concentrations.
These results demonstrate that both PRG4 and high
MW HA concentration can be limiting in achieving
reduction of friction in the boundary mode at a
cartilage-cartilage biointerface, and that both are
necessary contributors to the cartilage boundary lubri-
cating ability of SF. Furthermore, the addition of R/A
PRG4 to HA was unable to significantly reduce fric-
tion, indicating that PRG4’s tertiary and quaternary
protein structure is important in its friction reducing
synergism with HA at a cartilage-cartilage biointer-
face. Lastly, PRG4 + hylan G-F 20 demonstrated
improved lubricating ability compared to hylan G-F
20 alone, indicating that the HA + PRG4 cartilage
boundary lubrication synergism is also maintained
with a clinically relevant preparation of cross-linked
HA. Collectively, these results demonstrate that both
PRG4 and HA are necessary for effective friction re-
duction towards the level of whole SF and suggest
that deficiency of either or both may be detrimental
to SF cartilage boundary lubricating function.
The in vitro friction test used here is able to quantify
contributions of PRG4 and HA to friction reduction in
Fig. 3 Effect of HA concentration on cartilage boundary
lubricating ability. μstatic,Neq (a, b, c) for HA dose responses +
constant [PRG4] = 45 μg/mL (Test 2A, a), 150 μg/mL (Test 2B, b),
and 450 μg/mL (Test 2C, c). <μkinetic,Neq > at Tps = 1.2 s (d) for all
doses of HA in [PRG4] = 45, 150, 450 μg/mL (Test 2A, 2B, 2C).
Average < μkinetic,Neq > in PBS and SF shown in grey for reference.
# = significantly higher than [PRG4] = 450 μg/mL (p < 0.05). ^ =
significantly higher than [PRG4] = 150 μg/mL (p < 0.05)
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the boundary mode at a physiologically relevant cartilage-
cartilage biointerface. The test geometry, protocol, and
physiological surfaces allow for friction in a boundary
mode of lubrication to be measured, even in viscous HA
solutions - as indicated by the observation that PRG4 is
able to reduce friction in a dose dependent manner in
high MW HA solutions (3.3 mg/mL). While traditional
Stribeck curve analysis, originally developed for steel
surfaces, is not possible here given the rotational test
geometry that facilitates the depressurized, stationary area
of contact, its application to biointerfaces composed of
porous, hydrogels [30] (e.g. cartilage) has recently been
demonstrated to be not appropriate for biological tissues;
it is not able to account for the macromolecules present at
the deformable cartilage surfaces and in the non-
Newtonian lubricant solutions that contribute to friction
forces [31]. Though model surfaces provide the advantage
of well-defined sample surfaces and modes of lubrication,
and have been used to study wear prevention (previous
studies have shown that friction and wear are linked at the
articular surface [10]) as well as the order in which PRG4
and HA are adsorbed to surfaces [32], they may not allow
for all the operative physiological interactions at a
cartilage-cartilage biointerface to occur. The precise mo-
lecular mechanism through which boundary lubrication is
provided by PRG4 and HA in SF at the cartilage surfaces
(viscous boundary layer [33], adaptive mechanical control
[34]) remains to be fully clarified. However, the results
presented here are in general consistent with PRG4 +HA
Fig. 4 Effect of addition of R/A PRG4 on HA cartilage boundary
lubricating ability. μstatic,Neq (a), and <μkinetic,Neq> at Tps = 1.2 s (b)
for HA, HA + [R/A PRG4] = 450 μg/mL, and HA + [PRG4] = 450 μg/mL
(Test 4). * = p < 0.05
Fig. 5 Effect of addition of hylan G-F20 on PRG4 cartilage boundary
lubricating ability. μstatic,Neq (a), and <μkinetic,Neq> at Tps = 1.2 s (b)
for hylan G-F20 ± [PRG4] = 450 μg/mL (Test 3). * = p < 0.05
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functioning synergistically to reduce friction at a cartilage
surface through thick film boundary lubrication as pro-
posed by the adaptive multimodal mechanism [34].
This study used preparations of PRG4 and HA that
are representative of their composition within SF. The
PRG4 preparation contained both multimeric and
monomeric PRG4 species typically found in SF [27], and
the R/A preparation was deficient in the multimeric
PRG4 which could potentially occur in OA SF. A single
high MW HA preparation was used, with 1.5 MDa being
within the range of previously reported HA MW distri-
bution in normal and OA SF. [35, 36] Future studies
could examine the friction reducing ability of each PRG4
multimeric/monomeric species with HA at a cartilage-
cartilage biointerface, as well as an HA solution com-
posed of a mixtures of various MW HA at (patho)-
physiological concentrations to further examine the
potential concentration/MW dependence of the PRG4 +
HA synergism. Lastly, while a smaller number of repli-
cates has previously been used to assess differences
between lubricants [12], as the lubricating ability of the
solutions of interest become more similar in compos-
ition and low-friction function, a higher number of
replicates may help elucidate if the apparent subtle
differences observed here are in fact functionally
important.
The coefficients of friction obtained here are consist-
ent with previously measured values for purified solu-
tions of PRG4 and HA, alone and in combination, at a
cartilage-cartilage biointerface. <μkinetic,Neq > for PRG4 at
4.5 and 45 μg/mL observed in previous studies was on
the order of 0.2, while PRG4 at 450 μg/mL was 0.10 [5].
μstatic,Neq for PRG4 at 450 μg/mL observed in previous
studies was on the order of 0.4 [5]. The < μkinetic,Neq > ob-
tained here for HA at 0.3 mg/mL with PRG4 at 45 and
450 μg/mL (0.152, 0.073) are lower than previously ob-
tained for PRG4 alone, demonstrating friction reduction
compared to PRG4 or HA alone even when low concen-
trations of high MW HA are added to low concentra-
tions of PRG4. <μkinetic,Neq > for 1.5 MDa HA alone at
3.3 mg/mL was 0.080 in this study, and has been ob-
served to be approximately 0.09 [12]; the values ob-
served here with PRG4 (even 45 μg/mL, 0.072) appear
to be similar to 1.5 MDa HA alone, indicating that very
low concentrations of PRG4 can limit the boundary
lubricating ability of HA + PRG4 solutions. Previous
measurements of < μkinetic,Neq > for 450 μg/mL PRG4 +
3.3 mg/mL 1.5 MDa HA (0.046 [12]) are consistent with
the values observed in this study (0.054). Note that μsta-
tic,Neq is presented here as a representation of start-up
friction, and is calculated from the peak torque measure-
ment at start-up of motion. <μkinetic,Neq > is calculated
from the average torque in the final 2 revolutions of the
testing protocol, and is representative of steady-state
lubricating ability. Differences is trends between < μkine-
tic,Neq > and μstatic,Neq (ie. HA at 3.3 mg/mL + PRG4 at
150 μg/mL appears to be equivalent to 45 and 450 μg/
mL for μstatic,Neq but not for < μkinetic,Neq>) could be due
to the fact that there are differences in how friction is
reduced in start-up versus steady state motion.
This study provides insight into the effects that PRG4
tertiary and quaternary structure, which may be altered
during injury and disease, have on its functional inter-
action with HA. However, potential changes in PRG4
structure, including relative composition of multimers:-
monomers and fragments of PRG4 [14], remain to be
clarified. Previous preliminary results have demonstrated
that < μkinetic,Neq > of native PRG4 alone at 450 μg/mL is
increased 34 % upon R/A, providing evidence that the
disulfide-bonded structure of PRG4 itself is important
for boundary lubricating ability [16]. In this study, des-
pite a slight reduction in friction, the cartilage boundary
lubricating ability of HA alone and HA + R/A PRG4
were not significantly different, suggesting that degrad-
ation of PRG4 structure and/or assembly in SF could po-
tentially impact SF boundary lubricating ability by
altering the PRG4 +HA interaction. This suggests that
PRG4’s tertiary and quaternary protein structure is im-
portant in the interaction with HA. Future studies exam-
ining the role of PRG4 multimer/monomer interaction
with HA to reduce friction will help clarify this issue.
These results also demonstrate that PRG4 can further
reduce friction at a cartilage-cartilage biointerface, under
boundary mode lubrication, beyond that of a cross-
linked HA clinical product alone. Indeed, the < μkinetic,-
Neq > obtained for hylan G-F 20 at 3.3 mg/mL and PRG4
at 450 μg/mL (0.048) is very close to those discussed
above for PRG4 and 1.5 MDa HA. These results contrast
with previous observations using a similar in vitro cartil-
age boundary lubrication test, where it was observed
that hylan G-F 20 failed to lubricate as well as SF, and
failed to prevent chondrocyte apoptosis compared to SF.
[37] Subsequent work demonstrated that addition of
purified PRG4 to PRG4-void SF was able to decrease
chondrocyte apoptosis, and lower < μkinetic,Neq > beyond
that of PRG4 alone, suggesting again that the PRG4 +
HA interaction is critical for normal SF function [38].
While the studies investigating chondrocyte apoptosis
and boundary lubrication used a similar in vitro bound-
ary lubrication test setup as this study, overall values
may differ due to test parameter differences (no annular
geometry, less time for stress relaxation, live explants, 12
continuous cycles vs. start and stop). The observation
that PRG4 +HA friction reduction is not disrupted by
the cross-linking procedure is consistent with previous
evidence suggesting that the PRG4 +HA interaction is
not a specific site-dependent binding, but rather a phys-
ical interaction [12, 39]. The hylan G-F 20 used in this
Ludwig et al. BMC Musculoskeletal Disorders  (2015) 16:386 Page 8 of 10
study was diluted to 3.3 mg/mL from its clinical concen-
tration of 8 mg/mL to provide consistency with previous
studies characterizing the PRG4 +HA interaction and
investigate the effect of cross-linking. The effect of this
dilution on PRG4 +HA interaction is currently unclear,
and future studies elucidating the mechanism of the
PRG4 +HA interaction will provide insight into the
effects of supra-physiological HA concentrations and
their influence on interaction with PRG4 in vivo.
Conclusion
This study provides further insight into the nature of
cartilage boundary lubrication by SF constituents
PRG4 and HA. The results presented here demon-
strate the importance of both PRG4 and high MW
HA concentration, as well as PRG4 and HA structure
to their synergistic friction-reducing cartilage bound-
ary lubricating ability. These findings are consistent
with observations of cartilage boundary lubrication by
SF; when normal HA MW distribution and PRG4
content are decreased, lubricating ability is compro-
mised [13], but when normal HA MW distribution is
maintained with low PRG4 concentration, lubricating
ability is equivalent to that of normal SF. [40] As car-
tilage boundary lubrication synergism appears to be
lost when both PRG4 and high MW HA are present
in low concentrations, it is possible that a combined
PRG4 + HA intra-articular treatment may be able to
“rescue” SF deficient in either lubricant. Given that
combining PRG4 and HA in an intra-articular
biotherapeutic treatment may be able to impart the
benefits of both HA (pain relief, viscosity) and PRG4
(chondroprotection [23–26], and potentially viscosity
[28, 41]), characterizing and understanding the mo-
lecular mechanism(s) of the functional synergism
could be of great value in optimizing concentrations
and/or structural composition to further improve
current intra articular biotherapeutic treatments.
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